Risk for Shoulder Conditions Small After Vaccination in Deltoid Muscle
Incidence of shoulder conditions per 10,000 vaccinations was 1.22 for adults (age 18 years or older) and 0.05 for children (age 3 to 17 years)
Incidence of shoulder conditions per 10,000 vaccinations was 1.22 for adults (age 18 years or older) and 0.05 for children (age 3 to 17 years)
Limited evidence suggests that continuing biological DMARDs may lower risk for disease flares without increasing risk for postop complications
This slideshow shows drug information for Susvimo. Click here for the complete Susvimo monograph.
The ongoing phase 3 BE MOBILE 1 study compared the efficacy and safety of bimekizumab to placebo in adults with active nr-axSpA.
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
XT-150 is a locally injectable non-viral therapy expressing interleukin (IL)-10v, a proprietary modified variant of IL-10.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
In patients undergoing knee arthroplasty, postoperative incidence of venous thromboembolism lower with milvexian versus enoxaparin
At five years, no difference seen in symptoms, but rates of subsequent surgical treatment lower with methylprednisolone versus saline injection